Glutaminolysis (GLS) and Metabolic Dependency
Two Isoforms, Two Products
| Enzyme | Gene | Product | Note |
|---|---|---|---|
| GLS1, long form (KGA) | GLS | Glutamate + NH₄⁺ | Mitochondrial; the form most often targeted |
| GLS1, short form (GAC) | GLS | Glutamate + NH₄⁺ | Alternatively spliced; lacks the N-terminal domain |
| GLS2 | GLS2 | Glutamate + NH₄⁺ | Liver and brain; often tumour-suppressive context |
Important distinction. GLS produces glutamate, not α-ketoglutarate. The second step has two routes: glutamate dehydrogenase (GLUD1) releases ammonia and produces α-KG, while transaminases (GOT1/2, GPT, PSAT1) transfer the amino group to a keto acid and produce α-KG without releasing ammonia. The two routes differ in nitrogen handling and in the redox consequences, and a cell can switch between them.
This is why GLS inhibition does not always reduce α-KG supply to the extent expected: transaminase routes can sustain α-KG production from glutamate derived elsewhere, and glutamate can also be imported.
Part 1 — What Glutamine Is Used For
| Use | Route | Consequence of GLS inhibition |
|---|---|---|
| Anaplerosis | GLS → glutamate → α-KG → TCA | Reduced TCA intermediates; depends on alternative anaplerosis |
| Nitrogen donor | Amide N for nucleotides; amino N for transamination | Reduced nucleotide synthesis; amino acid imbalance |
| Glutathione synthesis | Glutamate exported via SLC7A11 for cystine import | Reduced cystine uptake and GSH, in cells dependent on this route |
| Reductive carboxylation | Glutamine → α-KG → citrate via IDH2, in hypoxia | Impaired lipogenesis from glutamine |
| Signalling | Intracellular glutamine and exchange-dependent leucine uptake | Reduced mTORC1 signalling |
Readout note. GLS inhibition affects all five. A phenotype after CB-839 therefore does not establish that anaplerosis was the relevant role. The discriminating experiments are rescues: cell-permeable α-KG for anaplerosis, nucleosides for nucleotide synthesis, NAC or β-mercaptoethanol for the glutathione route, and leucine for the exchange-dependent signalling route.
Part 2 — When Glutamine Becomes a Dependency
Dependency is a property of the medium and the cell together, not of the cell alone.
| Condition | Effect on glutamine dependence |
|---|---|
| High medium glutamine (4 mM) | Cells can often survive GLS inhibition by importing glutamate |
| Low medium glutamine (0.5–1 mM) | GLS becomes more important; dependence appears |
| Absent or low glucose | Glutamine oxidation supports the TCA cycle; dependence rises |
| Hypoxia | Reductive carboxylation dominates; GLS still required, IDH2 direction changes |
| High proliferation rate | Nucleotide demand rises; amide nitrogen requirement rises |
| Expression of alternative anaplerotic routes | Pyruvate carboxylation or propionyl-CoA can substitute |
Caveat on the standard experiment. Most glutamine-dependency work is performed in medium containing 2–4 mM glutamine, which is several-fold above plasma concentrations. A dependency demonstrated at 4 mM is a stronger claim than one demonstrated at 0.5 mM, because the higher concentration means the cell had more alternative substrate available. Reporting the concentration is therefore part of the finding.
Part 3 — Reductive Carboxylation
In hypoxia or when mitochondrial function is impaired, glutamine-derived α-KG can be converted to citrate by the reverse reaction of isocitrate dehydrogenase 2, supplying acetyl-CoA equivalents for lipogenesis.
| Feature | Oxidative route | Reductive route |
|---|---|---|
| Direction of IDH2 | Forward (citrate → α-KG) | Reverse (α-KG → citrate) |
| Oxygen requirement | High | Low |
| Carbon labelling pattern | Glutamine carbon into malate and aspartate | Glutamine carbon into citrate m+5, and into fatty acids |
| Readout | ¹³C-glutamine into malate | ¹³C-glutamine into citrate and palmitate |
Important distinction. The same tracer produces different labelling patterns depending on direction, which is why tracing — not enzyme expression — identifies the route. MTHFD2 expression, IDH2 expression and hypoxia markers are all consistent with either direction.
Part 4 — Testing a GLS Dependency
| Step | Measurement | What it establishes |
|---|---|---|
| 1 | Glutamine consumption and glutamate release | That glutaminolysis is active |
| 2 | ¹³C-glutamine into TCA intermediates | That carbon enters the cycle |
| 3 | GLS1 knockdown plus CB-839 | That the effect is on-target |
| 4 | Growth in reduced glutamine | That the requirement is concentration-dependent |
| 5 | Rescue panel: α-KG, nucleosides, NAC, leucine | Which role mattered |
| 6 | Ammonia measurement | Whether nitrogen disposal changed |
The fifth step is the one that converts the result into a mechanism, and the fourth is what makes it quantitative. A dependency that disappears at 4 mM glutamine but is present at 1 mM is a real dependency in the latter condition and should be reported as such.
Part 5 — Model Requirements and Recurring Failures
| Requirement | Why |
|---|---|
| Medium glutamine concentration stated | It determines the dependency |
| Medium age recorded | Glutamine degrades to ammonia at 37 °C |
| Glucose concentration stated | It competes with glutamine for the TCA cycle |
| Ammonia measured | A product and a signal |
| Proliferation measured | Demand scales with biomass |
| Transaminase route considered | It can substitute for GDH |
Recurring failures:
- • "GLS produces α-KG" stated as a single step, hiding the transaminase alternative.
- • CB-839 used at a single high concentration without an on-target control.
- • Rescue with α-KG at millimolar concentrations without considering osmotic and metabolic effects.
- • Dependency claimed at 4 mM glutamine and generalised to physiological conditions.
- • Ammonia not measured, although glutaminolysis is its main source in culture.
- • Reductive carboxylation inferred from expression rather than from labelling direction.
- • Glutamate import ignored, although it can bypass GLS entirely.
Part 6 — Where This Article Connects
This is the glutaminolysis article of the amino acid cluster, and it takes the pillar's five-role framework and applies it to one enzyme. The CB-839 protocol article covers dosing; the glutamine concentration article covers the medium variable that determines whether a dependency exists at all; the nucleotide and one-carbon articles cover the two downstream consumers that most often explain the phenotype.
If you need glutaminolysis measured with route-resolved tracing and a rescue panel, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
GLS isoform expression, transaminase use and dependency vary with cell type, medium composition, oxygen tension and proliferation. The conditions here describe principles, not thresholds for a specific model.
Inhibition of glutaminolysis does not establish which glutamine role was required, and a dependency demonstrated in one medium does not transfer to another.
Scientific interpretation and experimental design
- • GLS makes glutamate. α-KG needs a second step.
- • Two second steps. GDH releases ammonia; transaminases do not.
- • Dependency depends on the medium. State the glutamine concentration.
- • Reductive carboxylation is a labelling pattern. Expression cannot identify direction.
- • Rescue panel, not rescue compound. One rescue tests one role.
- • Ammonia is the product. Measure it.
Selected references for further reading
- • DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29:313–324.
- • Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nature Reviews Cancer. 2016;16:619–634.
- • Metallo CM, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2012;481:380–384.
- • Mullen AR, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481:385–388.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »